U.S. Markets close in 2 hrs
  • S&P 500

    3,835.55
    +4.16 (+0.11%)
     
  • Dow 30

    30,946.39
    -21.43 (-0.07%)
     
  • Nasdaq

    11,325.54
    +3.30 (+0.03%)
     
  • Russell 2000

    1,723.47
    -17.86 (-1.03%)
     
  • Crude Oil

    98.15
    -1.35 (-1.36%)
     
  • Gold

    1,735.50
    -28.40 (-1.61%)
     
  • Silver

    19.10
    -0.02 (-0.08%)
     
  • EUR/USD

    1.0192
    -0.0079 (-0.7644%)
     
  • 10-Yr Bond

    2.9060
    +0.0970 (+3.45%)
     
  • Vix

    27.49
    -0.05 (-0.18%)
     
  • GBP/USD

    1.1926
    -0.0026 (-0.2147%)
     
  • USD/JPY

    135.6780
    -0.1640 (-0.1207%)
     
  • BTC-USD

    20,272.79
    +574.24 (+2.92%)
     
  • CMC Crypto 200

    438.65
    +3.12 (+0.72%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Molecular Partners to Present at Upcoming Healthcare Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at two upcoming virtual healthcare investor events in September 2021.

Conference Presentation Details:

  • Event: Morgan Stanley 19th Annual Global Healthcare Conference

  • Date/Time: Friday, September 10, 11:00 AM – 11:45 AM ET (5:00 PM – 5:45 PM CET)

  • Event: H.C. Wainwright 23rd Annual Global Investment Conference

  • Date/Time: September 13-15, 2021; Presentation available on demand from Sept. 13, 7:00 AM ET (1:00 PM CET)

All webcasted presentations will be made available on the Molecular Partners website.

About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
www.molecularpartners.com; Follow the Company on Twitter at @MolecularPrtnrs.

CONTACT: FOR FURTHER DETAILS, PLEASE CONTACT: Seth Lewis, SVP IR, Comms, & Strategy seth.lewis@molecularpartners.com Tel: +1 781 420 2361 Shai Biran, Ph.D., Associate Dir. IR & Comms shai.biran@molecularpartners.com Tel: +1 978 254 6286 Thomas Schneckenburger, European IR & Media thomas.schneckenburger@molecularpartners.com Tel: +41 79 407 9952